PolyPid Ltd. (PYPD)

Market Cap	23.74M
Revenue (ttm)	n/a
Net Income (ttm)	-26.86M
Shares Out	6.80M
EPS (ttm)	-6.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,182
Open	3.600
Previous Close	3.620
Day's Range	3.225 - 3.600
52-Week Range	2.950 - 9.200
Beta	1.32
Analysts	Strong Buy
Price Target	12.00 (+243.84%)
Earnings Date	Nov 13, 2024

About PYPD

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2020
• Employees: 62
• Stock Exchange: NASDAQ
• Ticker Symbol: PYPD
• Website: https://www.polypid.com

Analyst Forecast

According to 2 analysts, the average rating for PYPD stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 243.84% from the latest price.

Price Target

$12.0

(243.84% upside)

Analyst Consensus: Strong Buy